35 results
Thumbnail

D1.151 - Changes in Treatment Steps After Biological Therapy in Patients with Severe Asthma: Real-World Data

Thumbnail

D1.139 - Dupilumab was Effective in Black and Non-Black Patients with Asthma Completing 1 Year of the RAPID Registry

Thumbnail

D1.140 - Beyond Severe Asthma: Eosinophilic Granulomatosis with Polyangiitis Unmasked by Acute Myopericarditis

Thumbnail

D1.141 - Added value of impulse oscillometry in the early detection of small airway dysfunction in asthma

Thumbnail

D1.142 - Clinical remission in long-term biological therapy of severe asthma

Thumbnail

D1.143 - Clinical Efficacy of Biologics and ATAD in NSAID-Exacerbated Respiratory Disease: A Phenotype-Based Comparative Study

Thumbnail

D1.144 - Eosinophilic myocarditis as a complication of dupilumab treatment

Thumbnail

D1.145 - Clinical Impact of Type 2 Phenotype in Severe Asthma Patients with Exacerbations During Biologic Treatment

Thumbnail

D1.146 - Improved nocturnal oxygenation in a severe allergic asthma patient with comorbid sleep apnea under anti-TSLP biologic therapy

Thumbnail

D1.147 - Efficacy of benralizumab in Chinese patients with severe eosinophilic asthma: subgroup analysis of the 16-week results from STEP, a phase IIIb study of step-down maintenance therapy

Thumbnail

D1.148 - Real-world effectiveness of dupilumab administered every 4 weeks in patients with moderate to severe asthma

Thumbnail

D1.149 - Healthcare Professionals Typically Apply Higher Blood Eosinophil Count Thresholds for Biologic Selection Versus Clinical Guidelines in Severe Asthma

Thumbnail

D1.150 - Patient characteristics and treatment patterns in adults with severe asthma in Poland (POLSAR): a retrospective, single-center real-world cohort from ISAR

Thumbnail

D1.152 - Treatment-induced remission after mepolizumab discontinuation: case series

Thumbnail

D1.153 - Indirect Comparison of Biological Agents in Severe Asthma: Real-World Data

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study